Emergent Biosolutions Inc (EBS)

[BTCDreamer]

And we know how well they're doing today! :)

[mick]

Emergent Biosolution (EBS)
88.45 ? 4.37 (5.20%)
Volume: 272,203 @07/06/20 11:52:45 AM EDT
Bid Ask Day's Range
- - 84.75 - 88.63
EBS Detailed Quote

[GM26]

And $VXRT ;)

[mick]

PARTNER WIT $NVAX, $EBS

[grow fast]

VistaTrades issued a BUY signal for EBS on 4.17.17

[stocktrademan]

EBS bullish 28.88

stochastics crossing up out of oversold

market overreacted to light vaccine order and may have misinterpreted
http://www.investors.com/news/technology/emergent-biosolutions-stock-plunges-on-light-anthrax-vaccine-order/?ven=YahooCP&src=AURLLED&ven=yahoo

stock usually recovers from these types of dips
low risk high reward chart

[Bluesummers]

An amazing company (would love to work for them some day).

Check out the Robinhood app (good for Android or IOS).

You can trade this company using that app for free.

Great way to start trading if you're new to the stock market (IMHO).

[$Pistol Pete$]

$EBS Daily and Weekly Charts

[$Pistol Pete$]

$EBS Daily Chart

[phryne]

I'd like to know how you checked his holdings out? I tried and failed.

[ShinSekai]

I think I'm on to something huge. Check out Dr. Robin Robinson's recent dealings to get ahead of the curve. Their are a few more stocks poised to run up. Unfortunately a lot of the others are private. This stock, however, is one of the few that are public. Higher Monday for sure. :) I may retire before I'm 30

[ShinSekai]

Yeah... I should've written hint hint wink wink. EBS was listed as an emergency facility in a government proposal by Dr. Robin Robinson. After some DD I figured it was only a matter of time. I hope this goes up Monday

[Contenders]

EBS in the news today.

Looking forward to the action next week.

http://news.yahoo.com/exclusive-u-requests-production-plans-ebola-drug-zmapp-183307513--finance.html

[ShinSekai]

We could sure use an Ebola vaccine contender.

[surf1944]

7:15AM Emergent BioSolutions BioSolutions announces 'positive' preclinical efficacy and PK Data for its new bispecific adaptir protein therapeutic ES414 at AACR; Treatment with ES414 showed statistically significant inhibition (EBS) 13.76 : The ES414 molecule was constructed using Emergent's ADAPTIR technology platform and selectively binds to the T cell receptor on cytotoxic T cells and Prostate Specific Membrane Antigen (PSMA), an antigen commonly found on prostate cancer cells.

Co announced the first poster, Emergent scientists described the efficacy of ES414 to prevent growth of human prostate cancer cells in vivo that express the PSMA protein on their surface: "Anti-PSMA x anti-CD3 ADAPTIR molecule inhibits tumor growth in vivo" Treatment with ES414 showed statistically significant inhibition of subcutaneous tumor outgrowth in the presence of human T cells in two independent mouse xenograft models of prostate cancer (C4-2B, MDA-PCa-2b). In both models, all treatment groups also showed a statistically significant decrease in serum PSA compared to negative controls.

Co announced The second poster described initial PK and tolerability: "Pharmacokinetic evaluation and tolerability assessment of anti-PSMA x anti-CD3 ADAPTIR molecule" These non-clinical studies showed that ES414 is pharmacologically active, has an extended serum half-life compared to antibody fragments, is well tolerated at levels well above the expected human dose, and possesses suitable characteristics for further in vivo toxicology studies.

[mlkrborn]

EBS $13.50 expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data (EBS) .
Emergent BioSolutions to expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data (EBS) 13.41 : Co announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL). The expanded protocol will include two new study cohorts to examine a lower dose of TRU-016 with rituximab in front line CLL and to evaluate the combination in relapsed CLL patients. This decision is based on strong patient enrollment along with encouraging early safety and efficacy data from this study. TRU-016 is the co's humanized anti-CD37 monospecific protein therapeutic, built on its ADAPTIRTM (Modular Protein Technology) platform, for the treatment of CLL. The co anticipates that this expanded clinical program will significantly enhance the value of TRU-016 and the company's active partnering program without impacting the company's total 2013 operating expenses.

TRU-016 is also currently being evaluated in a randomized, open label, active-controlled Phase 2 study in combination with bendamustine in patients with relapsed CLL. This study is on track to achieve its target enrollment of approximately 60 patients in April 2013.

[thepostman]

[mlkrborn]

EBS $17 on government contract... Rises above 52 weeks low level. Emergent BioSolutions gets $1.25B vaccine order
Emergent BioSolutions says US finalizes order of 44.8M doses of anthrax vaccine for $1.25B
ap

Related Quotes
Symbol Price Change
EBS 17.18 +1.75

On Monday October 3, 2011, 8:57 am EDT

ROCKVILLE, Md. (AP) -- Emergent BioSolutions Inc. said Monday that the U.S. government is formally ordering 44.8 million doses of the company's BioThrax anthrax vaccine in an agreement worth as much as $1.25 billion over five years.

Emergent said deliveries of the vaccine will start in 2011, with 8.5 million doses delivered in the first contract year. The company said in May that the government was planning to make the order.

Shares of Emergent BioSolutions closed at $15.43 Friday and have traded between $14.90 and $26.41 over the last 12 months.

[surf1944]

Fisher Investments' Healthcare Picks: Large Caps Trumping Small Caps

Emergent BioSolutions (EBS) is an American pharmaceutical company that developed an Anthrax vaccine and which is working on developing vaccines for Hepatitis, with a current market valuation of approximately $803 million.

http://seekingalpha.com/article/279378-fisher-investments-healthcare-picks-large-caps-trumping-small-caps?source=yahoo

[stockwinner]

Emergent BioSolutions awarded $106M BioTrax contract from FDA

[stockwinner]

yeah it has been trading around this range for the last 2 to 3 weeks! I just jumped in today and had a very good entry point.

[mlkrborn]

$15s now!

[stockwinner]

Good news so far. I think this is heading to the 20's + soon.

[mlkrborn]

down 1.33 to $13 'cause:
Shares of vaccine maker PharmAthene Inc. (PIP, $1.69, -$1.57, -48.16%) fell a day after the Department of Health and Human Services changed its approach in requesting anthrax vaccines. HHS canceled a request for proposals on recombinant protective antigen anthrax vaccine because it didn't believe vaccine developers submitting proposals could have product ready for licensure by the Food and Drug Administration within eight years.
Emergent BioSolutions Inc. (EBS, $12.52, -$1.88, -13.06%) also declined on the anthrax vaccine news, though it said the decision has no impact on its $400 million procurement contract with the Centers for Disease Control and Prevention for the delivery of 14.5 million doses of BioThrax--the only vaccine licensed by the FDA for the prevention of anthrax --into the Strategic National Stockpile.

[bell345]

I predict that ebs will move back to around 17.00, soon.

[dan heil]

starting to jump again

[bell345]

I'm excited about the bios this year because many are saying this will be a good year for them.

I'm already up a ton in TELK.

http://finance.yahoo.com/echarts?s=TELK#symbol=TELK;range=3m

[gcanderheggen]

Bell: I think you are right. Lets hope we both do well. geo

[bell345]

Biotech is a favorite group now, so EBS could go further then a lot of people expect.

[gcanderheggen]

Bell: Still got a good trend line. Wonder how long it will last. geo

[gcanderheggen]

Bell: Yes it did and that was during a down trend. geo

[bell345]

Last year at this time it dropped from 10 to 5 real fast.

http://finance.yahoo.com/q/bc?s=EBS&t=2y

[gcanderheggen]

Bell: It is doing well with both tech and fundamentals. So far it has weathered this storm. geo

[bell345]

I think it's was getting good exposure from Investor Business Daily.

[gcanderheggen]

So far EBS is weathering the financial storm. geo

[bell345]

Great balance sheet for a bio.

[gfp927z]

>>> Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services
Wednesday September 26, 8:00 am ET

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS - News), announced today that it has signed a three year contract with the U.S. Department of Health and Human Services (HHS), with a total value of up to $448 million. Components of the contract include:
(i) $400 million firm fixed-price for delivery of 18.75 million
doses of BioThrax(R) (Anthrax Vaccine Adsorbed) for inclusion
in the strategic national stockpile (SNS);
(ii) $34 million for receipt of regulatory approval of 4-year expiry
dating for BioThrax payable through a combination of a lump-
sum payment reflecting a price per dose increase for certain
doses delivered prior to approval and an increase in the per
dose price to be paid for doses delivered following approval;
(iii) up to $11.5 million in milestone payments in connection with
advancement towards a post-exposure prophylaxis (PEP)
indication for BioThrax; and,
(iv) $2.2 million for logistics services and other related support.

The Company anticipates making deliveries for approximately 6 million doses under this contract by year-end 2007. As a result, the company reaffirms its expectation for full year total revenue growth of 10 to 15 percent, with a bias toward the upper end of the range, and full year positive net earnings.

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, stated, "We are honored to continue our longstanding relationship with HHS to provide BioThrax as a critical component of our nation's biodefense stockpile. I applaud the dedication and professionalism of the senior leadership within HHS and Biomedical Advanced Research and Development Authority in completing this important step towards enhancing our domestic biodefense infrastructure. Emergent BioSolutions remains dedicated to working with various government agencies in their commitment to procure medical countermeasures as a primary element of establishing the highest possible levels of biopreparedness."

Under terms of the contract, HHS will purchase from the company an aggregate of 18.75 million doses of BioThrax through September 2010, for a firm, fixed-price of $400 million. In the event the company receives U.S. Food and Drug Administration (FDA) approval of the company's pending supplement to its biologics license application (BLA) to extend the shelf life of BioThrax from three years to four years, the company will receive a lump sum payment reflecting a price per dose increase for certain doses delivered prior to approval and an increase in the price per dose to be paid for doses delivered following the date of approval, with a total value of approximately $34 million. If FDA approval of 4-year expiry dating is not received during the term of the contract, the company will not be entitled to receive any of the $34 million. The company submitted its supplement for 4-year expiry dating to the FDA in December 2006 and has been providing additional information to the agency in support of its application.

Under the contract, HHS will also provide up to $11.5 million in connection with advancing the company's program to obtain a PEP indication for BioThrax. The PEP indication, which would expand the use of BioThrax beyond the current pre-exposure prophylaxis indication, is designed to permit the administration of BioThrax in combination with antibiotics following exposure to anthrax. These funds are payable upon the company's achievement of specific program milestones. The company anticipates that it will receive $8.8 million of this amount in the fourth quarter of 2007.

In addition, under the contract the company has agreed to provide all shipping services related to delivery of doses into the SNS over the contract term, and will receive payment of an additional $2.2 million.

The contract has been funded with Federal funding through the Project BioShield Special Reserve Fund, which was created by an act of Congress in May 2004.

Previously, Emergent BioSolutions has provided 10 million doses of BioThrax to HHS for inclusion in the SNS under a May 2005 supply agreement for 5 million doses valued at $123 million and a May 2006 contract modification for an additional 5 million doses valued at $120 million. <<<